Phaseline

Targets › YAP1

YAP1 (Transcriptional coactivator YAP1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2026.

Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signaling pathway, crucial for organ size control and tumor suppression by restricting proliferation and promoting apoptosis. (UniProt, P46937)

Open in Phaseline: the race on YAP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Medley TherapeuticsYAP101 (AAV9-Sav-shRNA)
AAV9-delivered short hairpin RNA targeting YAP1 to promote cardiac regeneration
YAP1Phase 1Heart Failure With Reduced Ejection FractionDec 2026

Conditions

Heart Failure With Reduced Ejection Fraction (1)

Modalities

other (1)

Companies

Medley Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.